See more : Black Pearl Group Limited (BPG.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Sapporo Clinical Laboratory Inc. (9776.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sapporo Clinical Laboratory Inc., a leading company in the Healthcare industry within the Healthcare sector.
- Aldel Financial Inc. (ADF) Income Statement Analysis – Financial Results
- CF Acquisition Corp. VII (CFFSW) Income Statement Analysis – Financial Results
- Insecticides (India) Limited (INSECTICID.BO) Income Statement Analysis – Financial Results
- PMV Pharmaceuticals, Inc. (PMVP) Income Statement Analysis – Financial Results
- Revival Gold Inc. (RVG.V) Income Statement Analysis – Financial Results
Sapporo Clinical Laboratory Inc. (9776.T)
About Sapporo Clinical Laboratory Inc.
Sapporo Clinical Laboratory Inc. operates dispensing pharmacies in Japan. The company offers clinical examination, pathological examination, and holter examination services. It provides food hygiene environmental inspection, including food/processed product, facility hygiene, and food handler inspection services; and radiation management services. In addition, the company develops, sells, and maintains software, such as SCAN clinical testing systems; and offers support services for opening new clinics. Further, it provides HiWeb21 inspection result inquiry services, as well as sells and maintains software relating to clinical testing. The company was incorporated in 1965 and is based in Sapporo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 19.68B | 20.13B | 19.11B | 17.50B | 17.66B |
| Cost of Revenue | 13.79B | 13.83B | 12.79B | 11.77B | 12.26B |
| Gross Profit | 5.90B | 6.30B | 6.32B | 5.73B | 5.40B |
| Gross Profit Ratio | 29.95% | 31.29% | 33.08% | 32.77% | 30.60% |
| Research & Development | 9.46M | 9.00M | 10.00M | 8.00M | 9.31M |
| General & Administrative | 131.58M | 138.94M | 141.66M | 125.04M | 123.00M |
| Selling & Marketing | 4.42B | 0.00 | 0.00 | 0.00 | 3.78B |
| SG&A | 4.55B | 138.94M | 141.66M | 125.04M | 3.90B |
| Other Expenses | 792.00M | 147.58M | 65.74M | 41.87M | -551.84M |
| Operating Expenses | 5.36B | 5.29B | 4.78B | 4.59B | 4.46B |
| Cost & Expenses | 19.15B | 19.12B | 17.57B | 16.36B | 16.71B |
| Interest Income | 135.00K | 216.00K | 276.00K | 346.00K | 4.00M |
| Interest Expense | 7.49M | 8.17M | 9.03M | 2.58M | 2.18M |
| Depreciation & Amortization | 535.59M | 519.10M | 547.00M | 271.27M | 244.73M |
| EBITDA | 1.14B | 1.49B | 2.06B | 1.45B | 1.09B |
| EBITDA Ratio | 5.80% | 8.35% | 11.28% | 8.35% | 6.74% |
| Operating Income | 534.51M | 1.01B | 1.54B | 1.14B | 945.96M |
| Operating Income Ratio | 2.72% | 5.01% | 8.04% | 6.53% | 5.36% |
| Total Other Income/Expenses | 63.44M | -48.84M | -35.08M | 33.58M | -99.68M |
| Income Before Tax | 597.95M | 959.70M | 1.50B | 1.18B | 845.26M |
| Income Before Tax Ratio | 3.04% | 4.77% | 7.86% | 6.72% | 4.79% |
| Income Tax Expense | 235.00M | 319.15M | 455.60M | 382.24M | 317.05M |
| Net Income | 380.16M | 568.62M | 1.04B | 793.69M | 528.20M |
| Net Income Ratio | 1.93% | 2.83% | 5.46% | 4.53% | 2.99% |
| EPS | 114.16 | 170.53 | 306.16 | 231.85 | 154.31 |
| EPS Diluted | 114.16 | 170.53 | 306.16 | 231.85 | 154.31 |
| Weighted Avg Shares Out | 3.33M | 3.33M | 3.41M | 3.42M | 3.42M |
| Weighted Avg Shares Out (Dil) | 3.33M | 3.33M | 3.41M | 3.42M | 3.42M |
Source: https://incomestatements.info
Category: Stock Reports